Needham sets USD 204.00 target for Neurocrine Biosciences stock

Published on 10/17/2026 at 19:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due November 2, 2026. Neurocrine Biosciences stock cost USD 135.71 on October 16, 2026, down 0.91 percent versus Nasdaq's prior close.

Analyst view and market position

Needham reaffirmed a Buy rating and set a USD 204.00 target on October 16, 2026.
Second-quarter revenue reached USD 959.00 million, up 39.50 percent year over year.
Neurocrine Biosciences stock closed at USD 135.71 on Nasdaq on October 16, 2026, down 0.91 percent versus the prior close.
Market capitalization stood at USD 13.8 billion and the price-to-earnings ratio was 19.90.

NBIX, US64125C1099, Illustration mit AI erstellt.

Needham & Company reaffirmed its Buy rating on Neurocrine Biosciences and set a USD 204.00 price target in a research note dated October 16, 2026, according to MarketBeat. The target is 50.40 percent above Neurocrine's USD 135.71 closing price. Neurocrine Biosciences stock closed at USD 135.71 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 0.91 percent versus the Nasdaq prior close.

Quarterly revenue sets the base

Neurocrine's second-quarter 2026 revenue reached USD 959.00 million, up 39.50 percent from the same quarter a year earlier. MarketBeat reported adjusted earnings per share of USD 2.85 against a USD 1.65 consensus estimate for that quarter. The result gives the November report a clear comparison point.

Stock stays above its yearly low

The Nasdaq price stood 11.11 percent above Neurocrine's 52-week low of USD 122.14 and 27.08 percent below its 52-week high of USD 186.12, both dated October 16, 2026. The stock's reported trading volume was 1,127,435 shares, versus an average volume of 1,222,842 shares on the same date, according to MarketBeat.

Valuation and November date

Neurocrine had a market capitalization of USD 13.8 billion and a price-to-earnings ratio of 19.90 on October 16, 2026. The company has scheduled its third-quarter 2026 financial results for November 2, 2026, with the press release at 4:00 p.m. ET and the conference call at 4:30 p.m. ET, according to Neurocrine Biosciences.

Comparison with peers

NBIX (Nasdaq, USD): minus 0.91 percent, P/E 19.90, market capitalization USD 13.8 billion, October 16, 2026.
Biogen (Nasdaq, USD): minus 1.15 percent, P/E 41.18, market capitalization USD 34.4 billion, October 16, 2026.
Vertex Pharmaceuticals (Nasdaq, USD): minus 1.77 percent, P/E 29.09, market capitalization USD 126.7 billion, October 16, 2026.

Next reporting checkpoint

The November 2, 2026 results will provide the next dated test for revenue growth, earnings and the distance to Needham's USD 204.00 target. Neurocrine is a biotechnology company focused on medicines for neurological, endocrine and psychiatric conditions.